Wedbush Securities Inc. Sells 3,272 Shares of AbbVie Inc. $ABBV

Wedbush Securities Inc. lowered its position in AbbVie Inc. (NYSE:ABBV) by 3.7% during the third quarter, according to its most recent filing with the SEC. The firm owned 85,034 shares of the company’s stock after selling 3,272 shares during the period. AbbVie accounts for approximately 0.6% of Wedbush Securities Inc.’s portfolio, making the stock its 27th largest position. Wedbush Securities Inc.’s holdings in AbbVie were worth $22,244,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of ABBV. Corient Private Wealth LP bought a new position in shares of AbbVie in the second quarter valued at $559,736,000. Legal & General Group Plc bought a new stake in AbbVie in the 2nd quarter valued at about $2,905,952,000. Jupiter Topco LLC purchased a new stake in shares of AbbVie during the second quarter worth $1,560,354,000. Diamant Asset Management Inc. boosted its position in shares of AbbVie by 21,649.0% in the first quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company’s stock valued at $798,456,000 after acquiring an additional 3,654,351 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in AbbVie during the second quarter valued at $817,473,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Up 0.2%

ABBV opened at $285.66 on Friday. The firm has a 50 day moving average price of $266.33 and a 200-day moving average price of $241.77. The stock has a market capitalization of $504.70 billion, a price-to-earnings ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $291.40.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period last year, the business posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie Inc. will post 13.93 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

Analysts Set New Price Targets

Several research firms have recently weighed in on ABBV. Wells Fargo & Company raised their price objective on shares of AbbVie from $295.00 to $300.00 and gave the company an “overweight” rating in a research report on Monday, August 17th. Bank of America reissued a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. UBS Group boosted their target price on AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research note on Tuesday, October 6th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price objective for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Finally, BMO Capital Markets increased their price target on shares of AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $279.86.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.